Abstract Purpose: To prepare some 2-morpholinomethylamino-4-(7-unsubstituted/substitutedcoumarin-3-yl)-6-chlorosubstitutedphenyl pyrimidines as antimicrobial agents.
INTRODUCTION
Microbial infections have been creating problems for mankind since centuries and scientists have also developed a large number of antimicrobial agents for the treatment of these infections. According to one new report, about 40 new microbial diseases have been identified since 1970s and more than 2 million Americans are suffering from antibiotic resistance, of which about 23,000 die each year [1] . Because of the development of antibiotic resistance and emergence of new microbial diseases, there is a need to develop new antimicrobial agents for the treatment of microbial infections.
Pyrimidine derivatives have an important place in medicinal chemistry as these are associated with a broad range of biological activities [2] [3] [4] including antioxidant activity [5] [6] [7] and antimicrobial activity [8] [9] [10] [11] [12] [13] . The clinical importance of pyrimidine nucleus is also evident by the marketing of clinically used pyrimidine derivatives as well as fused pyrimidine derivatives, for example, as antineoplastic agent (Tegafur), as vasodilator (Dipyridamole), as expectorant (Tasuldine) and as antibacterial agent (Trimethoprim, Piromidic Acid, Tetroxoprim, Metioprim), as antifungal agent (Flucytosine), and as antiviral agent (Broxuridine, Idoxuridine) [14] . Recently, the significance and biological importance of pyrimidine derivatives including their clinical applications in the microbial world has been reviewed [15] . The antimicrobial activity of pyrimidine derivatives against broad range of microbes makes it an important skeleton in medicinal chemistry and drug development against microbes. Morpholine nucleus is an integral part of linezolid, a clinically used drug for the treatment of infections caused by gram-positive bacteria [16] . A number of morpholine containing chemical compounds have also been reported as antimicrobial agents [17] [18] [19] [20] [21] [22] . Encouraged by these observations and also in continuation of our search for potent antimicrobial agents [23, 24] including antimicrobial agents having coumarin moiety [25, 26] , we decided to prepare some 2-morpholinomethylamino-4-(7-unsubstituted/substitutedcoumarin-3-yl)-6-chlorosubstitutedphenyl pyrimidines, herein after the title compounds (1a-18a), as antimicrobial agents.
EXPERIMENTAL General
Melting points were measured in open capillary tubes and are uncorrected. IR (KBr) spectra were recorded on a Nicolet, 5PC FT-IR spectrometer (Browser Morner, USA) and 1 H-NMR spectra on a Bruker DRX-300 FT NMR (Bruker, Germany) spectrophotometer using TMS as internal reference (chemical shift in δ ppm). Mass spectra were recorded on a Jeol-JMS-D-300 mass spectrometer (70 eV) (Jeol, Japan). Satisfactory analysis for C, H, and N was obtained for the compounds within ± 0.4 % of the theoretical values. Purity of the compounds was checked on silica gel G plates using iodine vapours as visualizing agent. R f value of the compounds was determined by using a mixture of benzene and acetone (9:1). All reagents used in the present work were of analytical grade. The synthetic pathway for the preparation of the title compounds (1a-18a) is provided in Fig. 1 .
The
2-amino-4-(7-substituted/unsubstituted coumarin-3-yl)-6-(chlorosubstitutedphenyl) pyrimidines (1-18) prepared according to our previous report [25] were reacted with morpholine and formaldehyde in absolute ethanol to provide the title compounds (1a-18a).
General method for the synthesis (1a-18a)
A mixture of 2-amino-4-(7-unsubstituted/ substituted coumarin-3-yl)-6-chlorosubstituted phenyl pyrimidines (0.01 mole), morpholine (0.01 mole) and formaldehyde (0.015 moles) was refluxed in absolute ethanol for 6 to 10 h. The reaction mixture was reduced to half of its volume and poured on crushed ice. The solid separated was filtered, washed with water repeatedly, dried and recrystallized from ethanol.
Evaluation of antimicrobial activity
The title compounds (1a-18a) were tested for their in vitro antimicrobial activity by serial plate dilution method [27, 28] 
Statistical analysis
All antimicrobial activity data are presented as mean ± SEM (n = 6). The data were analyzed by one-way analysis of variance (ANOVA) with Dunnett's Multiple Comparison Test with respect to control group and standard groups using GraphPad Prism version 5.00 for Windows (GraphPad Software, San Diego California USA). The results were considered significantly different at p < 0.05.
RESULTS
The title compounds (1a-18a) were prepared according to the method outlined in Fig 1. The characterization data of the intermediates, (C), (D) and (1-18) of the Fig. 1 were in line with our previously published data [25, 26] 
2-(Morpholinomethylamino)-4-(coumarin-3-yl)-6-(2,4-dichlorophenyl)pyrimidine (3a)
Yield : 
2-(Morpholinomethylamino)-4-(7-chlorocoumarin-3-yl)-6-(3,4-dichlorophenyl)pyrimidine (17a)
Yield
2-(Morpholinomethylamino)-4-(7-bromocoumarin-3-yl)-6-(3,4-dichlorophenyl)pyrimidine (18a)
Antimicrobial activity
The antimicrobial activity data of the title compounds (1a-18a) at different concentrations against Gram positive bacteria, Gram negative bacteria and fungi is provided in Table 1, Table 2 and Table 3 , respectively. For the explanation of the antimicrobial activity result this discussion, the zone of inhibition produced by the MIC of standard drugs, ofloxacin and ketoconazole, has been considered as 100 % for comparing the antibacterial activity and antifungal activity data of the title compounds (1a-18a), respectively.
The antibacterial activity of ofloxacin against Gram positive bacteria revealed that it has a MIC value of 25 μg/mL against S. aureus, E. faecalis and S. epidermidis; and it has a MIC value of 12.5 μg/mL against B. subtilis and B. cereus. The antibacterial activity of the title compounds (1a-18a) with respect to ofloxacin revealed that the compound 4a (MIC = 100 μg/mL) displayed highest activity of about 93.98 % with p < 0.05 against S. aureus; the compound 15a (MIC = 125 μg/mL) displayed highest activity of about 83.60 % with p < 0.0001 against E. faecalis; the compound 9a (MIC = 100 μg/mL) displayed highest activity of about 91.03 % (p < 0.0001) against S. epidermidis; the compound 14a (MIC = 150 μg/mL) displayed highest activity of about 88.5 % with p < 0.0001 against B. subtilis; and the compound 18a (MIC = 100 μg/mL) displayed highest activity of about 91.45 % with p < 0.0001 against B. cereus.
Some compounds exhibited good but statistically non-significant antibacterial activity results (p > 0.05) with respect to ofloxacin, for example, the compound 13a (MIC = 100 μg/mL) displayed about 99.88 % activity against S. aureus; compound 18a (MIC = 125 μg/mL) displayed about 94.75 % activity against S. aureus; and compounds 15a (MIC = 175 μg/mL) displayed about 98 % activity against S. epidermidis. The antibacterial activity produced by the compounds 4a, 9a, 13a, 14a, 15a and 18a was lower than the antibacterial activity produced by ofloxacin 3a, 5a, 7a, 9a, 10a, 11a, 16a , and 17a was lower than the antifungal activity produced by ketoconazole and they also had a higher MIC value than ketoconazole. Other compounds did not produced comparable antifungal activity against fungi even at higher concentrations with respect to ketoconazole.
DISCUSSION
A total of eighteen new compounds (1a-18a) were synthesized, and their structures were confirmed on the basis of their IR, 1 H-NMR, Mass and elemental analysis data. The characteristic peaks in 1 H-NMR spectra that confirmed the formation of the compounds (1a-18a) from the compounds (1-18) [25] were the appearance of the signals at δ (ppm) values from 2.63 to 2.72 for the four protons of -CH 2 -N-CH 2 -portion of the morpholine moiety; from 3.50 to 3.58 for the four protons of -CH 2 -O-CH 2 -portion of the morpholin moiety; and from 4.27 to 4.42 for the two methylene protons of -NH-CH 2 -moiety. The compounds (1a-18a) were tested for their in vitro antimicrobial activity by serial plate dilution method [27, 28] against five Grampositive bacteria; five Gram-negative bacteria; and five fungi.
Compound 3a (MIC = 75 µg/mL; p < 0.0001) and 15a (MIC = 125 µg/mL; p < 0.001) produced superior antifungal activity than the standard drug, ketoconazole (MIC = 25 µg/mL; p < 0.0001) against P. citrinum. Compound 4a (MIC = 100 μg/mL; p < 0.05) displayed highest but moderate activity against S. aureus with respect to the standard drug, ofloxacin (MIC = 25 µg/mL; p < 0.0001). Compound 4a (MIC = 75 μg/mL; p < 0.0001) also exhibited highest but moderate activity against E. coli with respect to the standard drug, ofloxacin (MIC = 12.5 µg/mL; p < 0.0001). Further, compound 4a showed less activity than ofloxacin and also had higher MIC values than the standard drug ofloxacin. It is evident from the antimicrobial activity data mentioned in Table 1, Table 2, and Table 3 that the title compounds are better antifungal agents than antibacterial agents. This is contrary to our earlier reported work [25] . This shows that the addition of the morpholine moiety to these type of compounds [25] increases their antifungal activity. Accordingly, there is a possibility that the replacement of the morpholine moiety by its bioisosteres, for example piperidine moiety, in these compounds may also produce promising antifungal compounds. Accordingly, this study may be extended to acquire more information about the structure activity relationships of these type of compounds. It is also believed that the synthesized compounds might be inhibiting the growth of all tested microorganism by same mechanism as earlier reported pyrimidine moiety containing drugs [15] .
The structure activity relationship study of the title compounds (1a-18a) revealed that the chloro substitution with respect to positions 2, 3 and 5 of the phenyl ring along with a chloro/bromo substituted coumarin moiety are critical for activity against Gram positive bacteria; the chlorosubstitution with respect to positions 2, 3, and 4 of the phenyl ring along with a chloro/bromo substituted coumarin moiety are critical for activity against Gram negative bacteria; the chlorosubstitution with respect to positions 2, 4, and 6 of the phenyl ring along with a chloro substituted coumarin moiety are critical for activity against fungi; the chloro substitution at position 2 of the phenyl ring along with a chloro/bromo substituted coumarin moiety is relatively more critical for activity against Gram positive bacteria, Gram negative bacteria and fungi.
CONCLUSION
It is evident from the antimicrobial activity data of the title compounds (1a-18a) that the compounds 3a and 15a produced higher antifungal activity than standard drug ketoconazole against P. citrinum. However, these compounds produced superior effect at higher concentration, and therefore, are considered to be less potent than ketoconazole. Some of the compounds displayed promising antibacterial activity at higher concentrations. It is also evident that the title compounds are better antifungal agents than as antibacterial agents. These compounds may be modified to achieve more potent antimicrobial activity. Accordingly, further studies to acquire more information about structure activity relationships are in progress in our laboratory.
